...
首页> 外文期刊>Biomaterials Science >A once-a-day dosage form for the delivery of insulin through the nasal route: in vitro assessment and in vivo evaluation
【24h】

A once-a-day dosage form for the delivery of insulin through the nasal route: in vitro assessment and in vivo evaluation

机译:通过鼻腔途径递送胰岛素的每日一次剂型:体外评估和体内评估

获取原文
获取原文并翻译 | 示例
           

摘要

An in situ thermogelling, mucoadhesive formulation based on N-trimethyl chitosan chloride has been evaluated for its potential to affect the transmucosal delivery of insulin via the nasal route. In vitro studies at a physiologically relevant temperature (ca. 35℃) have shown that the formulation releases most of its insulin load (ca. 70%) in a non-Fickian manner during the timescale over which the sol-to-gel transition (ca. 8 min) takes place, and also that, once gelation is complete, the release of the remainder of the therapeutic content follows first order kinetics over at least sixty minutes. Investigations on the effects of the application of the same formulation to a modelled nasal mucosa (Calu-3 cell monolayer) have indicated the capability of the formulation to induce the transient opening of tight junctions. Cytotoxic investigations have shown that the formulation exhibits negligible detrimental effects to the integrity of these monolayers. The in vivo potential of the nasal formulation to act as a once-a-day dosage form for the intranasal delivery of insulin has been demonstrated in a diabetic-rat model.
机译:已经评估了基于N-三甲基壳聚糖氯化物的原位热凝胶粘膜粘附制剂通过鼻途径影响胰岛素经粘膜递送的潜力。在生理相关温度(约35℃)下的体外研究表明,该制剂在溶胶至凝胶转变的时间范围内以非菲克式的方式释放了大部分胰岛素负荷(约70%)。约8分钟),并且一旦胶凝完成,其余治疗成分的释放将在至少60分钟内遵循一级动力学。对将相同制剂应用于模型化的鼻粘膜(Calu-3细胞单层)的影响的研究表明,该制剂具有诱导紧密连接的瞬时开放的能力。细胞毒性研究表明,该制剂对这些单层的完整性表现出可忽略的有害作用。在糖尿病大鼠模型中已经证明了鼻制剂作为胰岛素鼻内递送的每日一次剂型的体内潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号